Loading…
Novum Pharmaceutical Research Services
Accepting sponsorsFull-service global CRO
Request a proposalOpen roomSubmit RFPiRequest for Proposal — a formal request asking shortlisted companies to propose their full approach, scope and pricing.Compare
About
Novum Pharmaceutical Research Services is a full-service contract research organisation providing end-to-end clinical research services to the global innovator, biotech and generic pharmaceutical industries. Stated service lines are scientific affairs, Phase I early clinical development, bioanalytical, biosimilars development, Phase II-IV clinical trial management, data management and support services. The company was acquired by Lambda Therapeutic Research in 2019 and is the group's operating brand in North America.
Deterministic scores · rules-based, not AIiHow these scores are obtained: each one is computed from this profile's listed attributes — capability checkboxes, certifications, capacity figures and coverage — by a fixed formula, recomputed on every page load. Deterministic and rules-based means the score comes from a fixed, transparent formula over listed attributes — the same inputs always produce the same score. It is not AI: there is no model, no learning, and no hidden weighting. Whether a score is relevant to you depends on your specific project: a capability that raises the number may not matter for your work, and a niche strength your project needs may barely move it. Capability scores are a directional starting point, not a verdict. A lower score does not disqualify a company or consultant, and no decision should rest on the score alone — always contact the company directly to confirm the specifics for your project.
Sterile focus iMeasures how much of this CRO's trial work targets sterile and advanced-therapy products. A declared sterile-pharma focus adds 25 points; each sterile-relevant modality listed (biologics, cell and gene therapy, vaccines, radiopharmaceuticals, sterile injectables, mRNA/LNP, ADCs) adds 9 points up to 45; each advanced therapeutic area (oncology, rare disease, cell and gene, vaccines, radiopharma) adds 8 points up to 30. Levels: 75+ Sterile / advanced-therapy specialist | 50-74 Advanced-therapy active | 25-49 Selective | below 25 General clinical. Whether this dimension matters for you depends on your specific project.
0General clinical
Clinical scale iCombines geographic reach and operating breadth: countries covered earn half a point each up to 25, the site network and active-trial counts are scored on a log scale (up to 25 and 20 points, so growth matters most at smaller sizes), each service line adds 2 points up to 15, and each trial phase covered adds 3 points up to 15. Levels: 80+ Global full-service | 60-79 Multi-region | 40-59 Regional specialist | below 40 Boutique. Whether this dimension matters for you depends on your specific project.
18Boutique
CTMS health iLooks only at active studies (enrolling, ongoing, or in startup). Average enrollment progress against target is worth up to 45 points, average site activation up to 35, and a 20-point risk buffer loses 7 points for each high-risk study. Shows 0 with No active studies when nothing is currently active. Levels: 80+ On track | 60-79 Healthy | 40-59 Watch | below 40 At risk. Whether this dimension matters for you depends on your specific project.
0No active studies
Site oversight iAverages oversight quality across non-closed sites: source data verification completeness is worth up to 30 points, the share of queries resolved up to 25, the fraction of audit-ready sites up to 20, and a 25-point risk buffer loses 4 points per high-risk site and 3 per overdue monitoring visit. Shows 0 with No sites when no live sites are reported. Levels: 85+ Inspection-ready | 65-84 Well-controlled | 45-64 Monitor closely | below 45 At risk. Whether this dimension matters for you depends on your specific project.
0No sites
Biostat iAdds points for statistical methods (Bayesian 15, adaptive designs 15, real-world-evidence integration 10), each CDISC standard supported (5 points, up to 20), each analysis software platform (5 points, up to 15), and the data-integrity level (ALCOA+ validated 25, Established 15, Basic 5). Levels: 80+ Advanced data science | 60-79 Strong biometrics | 40-59 Established | below 40 Developing. Whether this dimension matters for you depends on your specific project.
0Developing
Pharmacovigilance iAdds points for core safety capabilities: a named safety database (15), MedDRA coding (10), literature surveillance (10), and E2B R3 submissions (15), plus 5 points per PV region covered up to 25, and annual case volume scored on a log scale up to 25 points. Levels: 80+ Global PV operation | 60-79 Established PV | 40-59 Developing | below 40 Basic. Whether this dimension matters for you depends on your specific project.
0Basic
Medical writing iCounts document breadth (4 points per document type, up to 25) and submission breadth (5 points per submission type, up to 25), adds 15 points each for eCTD capability and publishing capability, and scores the medical-writer headcount on a log scale up to 20 points. Levels: 80+ Full regulatory writing | 60-79 Strong medical writing | 40-59 Established | below 40 Developing. Whether this dimension matters for you depends on your specific project.
0Developing
Capability scores are a directional starting point, not a verdict. A lower score does not disqualify a company or consultant, and no decision should rest on the score alone — always contact the company directly to confirm the specifics for your project.
Trial phases
Phase IPhase IIPhase IIIPhase IV
Services
CTMS / study managementBioanalytical / labsData management
NPR
Novum Pharmaceutical Research Services
Contract research org · United States
Live record · illustrative seed data · scores deterministic, rules-based — not AI.